Researcher Marketers

 IMARC Group, a leading market research company, has recently releases report titled “ Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032 ”, Offers a comprehensive analysis of the industry, which comprises insights on the global oncology based in-vivo CRO market . How Big is the Oncology Based In-Vivo CRO Market? The global oncology based in-vivo CRO market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. Industry Overview of Medical Oncology Based In-Vivo CRO Oncology is a medical discipline focused on studying, diagnosing, and treating cancer through various techniques. The role of an oncology-based in-vivo CRO includes conducting various activities such as tum...

  Market Overview : According to the latest report by IMARC Group, titled "Global Oncology Based In-vivo CRO Market Size, Share, Industry Trends, Growth, Opportunity and Forecast 2022-2027 ", the global oncology based in-vivo CRO market reached a value of US$ 1.05 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.69 Billion by 2027, exhibiting a CAGR of 7.81% during 2022-2027. Oncology is a branch of medicine that studies, diagnoses, and treats cancer using various methods such as biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), and positron emission tomography (PET) scanning. On the other hand, oncology based in-vivo CRO refers to the method of treating cancer using contract research organization services. These services conduct research with living organisms such as animals, plants, or whole cells for pharmaceutical, biotechnology, and medical device industries on a contractual basis. In ...